Clinical trials
Graft vs Host Disease trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
45 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 8 |
| 2018 | 5 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 8 |
| Recruiting | 6 |
| Unknown status | 4 |
| Active, not recruiting | 3 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| IRCCS Azienda Ospedaliero-Universitaria di Bologna | 4 |
| Incyte Corporation | 4 |
| Novartis Pharmaceuticals | 4 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2 |
| Bambino Gesù Hospital and Research Institute | 2 |
| Ciceri Fabio | 2 |
| Kiadis Pharma | 2 |
| Mallinckrodt | 2 |
| Pharmacyclics LLC. | 2 |
| University of Pisa | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Graft vs Host Disease | 45 |
| Bronchiolitis Obliterans Syndrome | 7 |
| Hematologic Neoplasms | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Multiple Myeloma | 3 |
| Myelodysplastic Syndromes | 3 |
| Hodgkin Disease | 2 |
| Leukemia | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
Trials
Showing 26 to 45 of 45. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.